LABGENIUS
LabGenius, a pioneer in the use of machine learning (ML) for antibody-based drug discovery, today announced that it has been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK. With this recent grant, LabGenius has secured a total of over £1 million in government backing this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005020/en/
LabGenius is pioneering the development of an ML-driven protein engineering platform (EVA™). To date, EVA has co-optimised mono- and multi-specific single domain antibodies for biochemical and biofunctional properties, including stability, potency and selective tumour cell killing.
There are many different types of solid tumours that would benefit from highly selective immunotherapy treatments. This grant will be used to support the development of LabGenius’ pipeline of antibody therapeutics by financing the discovery of best-in-class immune cell engager molecules with favourable selective killing profiles. To do this, LabGenius will use its platform technology to intelligently guide the search for protein designs that perform across multiple therapeutically valuable properties.
“We’re truly delighted with this result” said LabGenius’ CEO and Founder, Dr. James Field. “This grant will enhance LabGenius’ ability to optimise an important class of immunotherapeutics and help us to accelerate drug candidates towards the clinic.”
Speaking to LabGenius’ success, Chairman of LabGenius’ Board and former CEO of Ablynx, Dr. Edwin Moses commented “This is a great win for LabGenius as it further validates their ML-driven approach to antibody discovery. With this backing, the team can further expand their efforts to build a strong pipeline of molecules that would not have been identified through rational human design alone.”
– end –
About LabGenius
Headquartered in London, LabGenius is a leading machine learning-driven protein engineering company. The company’s core technology platform, EVA™, enables the rapid discovery of novel therapeutic antibodies. LabGenius’ highly multidisciplinary team brings together the very best minds from the fields of computer science, robotic automation and synthetic biology.
For more information, please visit www.labgeni.us, or connect on Twitter, LinkedIn and Medium.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005020/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DNIB.com Reports Internet Has 378.5 Million Domain Name Registrations at the End of the Third Quarter of 202523.10.2025 23:00:00 CEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the third quarter of 2025 closed with 378.5 million domain name registrations across all top-level domains (TLDs), an increase of 6.8 million domain name registrations, or 1.8% compared to the second quarter of 2025. Domain name registrations also increased by 16.2 million, or 4.5%, year over year. The .com and .net TLDs had a combined total of 171.9 million domain name registrations in the domain name base at the end of third quarter of 2025, an increase of 1.4 million domain name registrations, or 0.8% compared to the second quarter of 2025. The .com and .net TLDs had a combined increase of 2.4 million domain name registrations, or 1.4%, year over year. As of Sept. 30, 2025, the .com domain name base totaled 159.4 million domain name registrations and the .net do
Copeland Expands Industrial Heat Pump Portfolio with Agreement to Acquire SPH Sustainable Process Heat23.10.2025 22:30:00 CEST | Press release
Acquisition enhances Copeland’s industrial heating portfolio Copeland, a global leader in sustainable climate solutions, today announced its agreement to acquire SPH Sustainable Process Heat (SPH), a Germany-based industrial heat pump technology company. This acquisition is expected to expand Copeland’s industrial heating portfolio, allowing the company to deliver a broader range of key heat pump technologies and solutions to new and existing customers. Copeland’s industrial business operates under the brand name Vilter. SPH will continue to operate independently until closing. This acquisition reinforces Copeland’s commitment to enabling the energy transition, in this case, through innovative technologies that enable industrial customers to replace fossil-fuel systems with more energy-efficient heating alternatives. SPH brings a strong technology portfolio, including its innovative ThermBooster™ technology, and demonstrated capability in delivering solutions to a broad range of indust
NIQ Publishes 2025 ESG Progress Report: Advancing Integrity, Innovation, and Impact23.10.2025 22:05:00 CEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2025 Environmental, Social, and Governance (ESG) Progress Report, covering its progress in 2024 and underscoring the company’s commitment to responsible business, data integrity, and inclusive growth across its global operations. “As a leading consumer intelligence company, our responsibility extends far beyond the industries we serve,” said Jim Peck, Executive Chairman and CEO of NIQ. “This year’s ESG Progress Report demonstrates how we are embedding sustainable and inclusive principles into our business, driving value for our clients, investors, associates, and communities.” Key progress areas from 2024Strengthened ESG governance: NIQ formalized its internal ESG governance framework and initiated a Double Materiality Assessment, aligning with the latest global standards and regulations. Advanced data integrity and security: The company advanced its use of AI and machine learning to ensure data quality, priva
Andersen Consulting udvider sine digitale transformationskompetencer med MOYO23.10.2025 19:47:00 CEST | Pressemeddelelse
Andersen Consulting fortsætter med at styrke sine transformationskompetencer inden for teknologi og forretning via en samarbejdsaftale med MOYO, der er et digitalt konsulenthus, som leverer integrerede løsninger inden for strategi, data, teknologi, programmering og talentudvikling. MOYO, der blev grundlagt i 2007 af administrerende direktør Pierre le Roux, kombinerer tjenester inden for rådgivning, teknologi og humankapital-tjenester for at hjælpe en bred kundebase – fra startups til store virksomheder inden for finansielle tjenester, minedrift og detailhandel – med at implementere skalerbare systemer, optimere processer og levere skræddersyede løsninger, der udnytter nye muligheder i den digitale økonomi. "Hos MOYO mener vi, at digital transformation kun lykkes, når løsninger skabes med dyb empati og en klar forståelse for menneskene bag virksomheden," sagde Pierre. "Vores samarbejde med Andersen Consulting afspejler det samme engagement i at skabe meningsfulde, langsigtede forandring
Berry Consultants Releases FACTS 8 Clinical Trial Simulator23.10.2025 19:00:00 CEST | Press release
FACTS 8 introduces support for Ordinal endpoints and a new “Quick Start” feature Berry Consultants, LLC announced the release of FACTS 8, the latest version of its industry-leading Fixed and Adaptive Clinical Trial Simulator (FACTS). FACTS 8 is now available to both existing users and new clients worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023501254/en/ FACTS is the most powerful, flexible, and efficient platform for designing and simulating clinical trials across the full spectrum of drug development — from early Phase I studies to complex, multi-arm platform trials. The new release introduces two major advancements: Full simulation of ordinal endpoints in Phase II and Phase III trial designs, enabling powerful designs with frequentist and Bayesian methods of analysis. A Quick Start feature that streamlines setup for fixed and group sequential trials while maintaining the full simulation power FACTS provide
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom